1. Vosoritide: first approval;Duggan S;Drugs,2021
2. C-type natriuretic peptide analogue therapy in children with achondroplasia;Savarirayan R;N Engl J Med,2019
3. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial;Savarirayan R;Lancet Child Adolesc Health,2024
4. European Medicines Agency. EU/3/12/1094 - Orphan designation for treatment of achondroplasia. (2013). Accessed. April 9, 2024: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1094.
5. BioMarin Pharmaceutical Japan Inc.. VOXZOGO® dosing guide. (Article in Japanese). (2024). Accessed: April 9, 2024: https://www.bmrn.co.jp/cms/wp-content/themes/biomarin/pdf/physicians/bmrn_voxzogo_04.pdf.